Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety

Clinical Therapeutics

Volumn 20, Issue 1, 1998, Pages 58-71

  Davies, Alison ^a   Adena, Michael A ^b   Keks, Nicholas A ^c   Catts, Stanley V ^d   Lambert, Tim ^e   Schweitzer, Isaac ^f  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b Instat Pty Ltd   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e Vic Transcultural Psychiatry Unit   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Efficacy; Haloperidol; Meta analysis; Risperidone; Safety

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; META ANALYSIS; PATIENT COMPLIANCE; SCHIZOPHRENIA;

EID: 0031930663     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80034-9     Document Type: Review

References (36)

1. Janssen PAJ, Neimegeers CJE, Awouters F, et al. Pharmacology of risperidone (R64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonist properties. J Pharmacol Exp Ther. 1988;244: 685-693.
2. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988;247:661-670.
3. Johnstone EC, Crow TJ, Frith C. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978;1:848-851.
4. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs - in vitro and in vivo receptor binding. Psychopharmacology. 1996;124:57-73.
5. Borison RL, Chu C-C, Gosenfeld L, et al. Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical Research Report on R64766 RIS-USA-9001, August 1991. Janssen Pharmaceutica, Beerse, Belgium.
6. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.
7. Marder SR, Meibach RC, and the Risperidone Study Group. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
8. Peuskens J, and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: A multinational, multicenter, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166:712-716.
9. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenia in inpatients: A multicenter, double-blind comparative study. Acta Psychiatr Scand. 1992;85:295-305.
10. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996;16:38-44.
11. Eysenck H. Meta-analysis and its problems. Br Med J. 1994;309:789-792.
12. Thompson SG, Pocock SJ. Can meta-analysis be trusted? Lancet. 1991;338: 1127-1130.
13. Goodman SN. Have you ever meta-analysis you didn't like? Ann Intern Med. 1991;114:244-246.
14. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188.
16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;16:261-276.
17. Overall JF, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10:799-812.
18. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993;26: 121-124.
19. Min SK, Rhee CS, Kim CE, Kang DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A parallel group, double-blind comparative trial. Yonsei Med J. 1993;34: 179-190.
20. Mesotten F. Risperidone versus haloperidol in chronic psychotic patients: A multicentre double-blind study. Clinical Research Report on RIS-BEL-7, August 1991. Janssen Research Foundation Beerse, Belgium.
21. Serejskij MJ. Terapija psichiceeskich zabolevanij. Medgiz Moskva. 1948.
22. Davies A, Langley PC, Keks NA, et al. Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther. 1997;19:196-213.
23. Risperdal approved product information. Janssen-Cilag Pty. Ltd., Lane Cove, New South Wales, Australia.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association; 1987:187-198.
25. Manual of the International Classification of Diseases, Injuries and Causes of Death Bused on the Recommendations of the Ninth Revision Conference. Geneva: World Health Organization; 1977:182-185.
26. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis. Int Clin Psychopharmacol. 1995;10:207-213.
27. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Rating Scale. Can J Neurol Sci. 1980;73:233.
28. Kane JM. Risperidone. Am J Psychiatry. 1994;151:802-803.
29. Victorian Drug Usage Advisory Committee Psychotropic Drug Guidelines 1993. 2nd ed. North Melbourne, Australia: Victorian Medical Postgraduate Foundation, Inc.; 1993:68.
30. Reynolds JEF, ed. Martindale: The Extra Pharmacopoiea. 31st ed. London: Royal Pharmaceutical Society; 1996:714-715.
31. Frances A, Docherty JP, Kahn DA. Treatment of schizophrenia. J Clin Psychiatry. 1996;57(Suppl 12B):25.
32. Australian Medical Index. Crows Nest, Australia: IMS Australia; Jan-March 1994, vol. 4.
33. Van Putten T, Marder SR, Mintz J, et al. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry. 1990;47: 754-758.
34. Umbricht D, Kane JM. Risperidone safety and efficacy. Schizophr Bull. 1995;21: 593-606.
35. Borison RJ. Clinical efficacy of serotonin-dopamine antagonists relative to classical neuroleptics. J Clin Psychopharmacol. 1995;15(Suppl 1):24S-29S.
36. Song F, Sheldon T. Meta-analysis of relative efficacy and side effects of risperidone in the treatment of schizophrenia. Pharmacoepidemiol Drug Saf. 1995;4 (Suppl 1):S5. Abstract.